FDA Inspection 1118897 — Incyte Corporation
The FDA completed an inspection of Incyte Corporation on Feb 10, 2020 in Wilmington, DE. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 10, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Wilmington, DE (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)